|
rs1360485
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition, the presence of one G allele in SNPs rs1360485 or rs2249825 was associated with a higher risk of progressing to T2 tumor and distant metastasis amongst HER2-enriched and triple-negative breast cancer (TNBC) tumors compared with luminal A and luminal B tumors.
|
29725248 |
2018 |
|
rs1412125
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Furthermore, having one C allele in the rs1412125 domain increased the risk of pathologic grade 3 disease in HER2-enriched and TNBC tumors.
|
29725248 |
2018 |
|
rs142030651
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A point mutation in the adenoviral E1A binding protein p300 (EP300-G211S) was significantly correlated to this TNBC subgroup.
|
30132219 |
2018 |
|
rs1651654
|
|
|
0.010 |
GeneticVariation |
BEFREE |
As shown in this analysis, rs1651654 and exm585172 SNPs are found to be determinants of TNBC risk.
|
28918577 |
2018 |
|
rs1801157
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The present study analyzed genetic polymorphisms in CXCL12 (rs1801157, G > A) and CXCR4 (rs2228014, C > T) and CXCR4 immunostaining in tumor tissues from patients with triple negative breast cancer (TNBC) aiming to evaluate their possible role in its' susceptibility and prognosis.
|
29926386 |
2018 |
|
rs200928781
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CONCLUSIONS Our findings indicated that CHEK2 Y390C mutation induced the drug resistance of TNBC cells to chemotherapeutic drugs through administrating cell apoptosis and cell cycle arrest via regulating p53 activation and CHEK2-p53 apoptosis pathway.
|
29761796 |
2018 |
|
rs2020912
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Whole exome sequencing in triple negative breast cancer cases (n = 8) and targeted sequencing in healthy controls (n = 48) revealed BRIP1 rs552752779 (MAF: 75% vs. 6.25%, OR 45.00, 95% CI 9.43-243.32), ERBB2 rs527779103 (MAF: 62.5% vs. 7.29%, OR 21.19, 95% CI 5.11-94.32), ERCC2 rs121913016 (MAF: 56.25% vs. 7.29%, OR 16.34, 95% CI 4.02-70.41), MSH6 rs2020912 (MAF: 56.25% vs. 1.04%, OR 122.13, 95% CI 12.29-2985.48) as risk factors for triple negative breast cancer.
|
30136158 |
2018 |
|
rs2228014
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The present study analyzed genetic polymorphisms in CXCL12 (rs1801157, G > A) and CXCR4 (rs2228014, C > T) and CXCR4 immunostaining in tumor tissues from patients with triple negative breast cancer (TNBC) aiming to evaluate their possible role in its' susceptibility and prognosis.
|
29926386 |
2018 |
|
rs2249825
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition, the presence of one G allele in SNPs rs1360485 or rs2249825 was associated with a higher risk of progressing to T2 tumor and distant metastasis amongst HER2-enriched and triple-negative breast cancer (TNBC) tumors compared with luminal A and luminal B tumors.
|
29725248 |
2018 |
|
rs3212986
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The rs11615 and rs3212986 of ERCC1 were investigated and evaluated for their associations with susceptibility to breast cancer, especially TNBC, in Taiwan.
|
30096175 |
2018 |
|
rs4415084
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After grouping breast cancer subtypes, significantly reduced survival was associated with the variant alleles of rs9485372 for luminal A and rs4415084 for triple negative breast cancer.
|
30285756 |
2018 |
|
rs473543
|
|
|
0.010 |
GeneticVariation |
BEFREE |
ATG5 rs473543 genotypes may serve as a potential marker for predicting recurrence of early-stage TNBC patients who received anthracycline-and/or taxane-based regimens as adjuvant chemotherapy.
|
29382381 |
2018 |
|
rs527779103
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Whole exome sequencing in triple negative breast cancer cases (n = 8) and targeted sequencing in healthy controls (n = 48) revealed BRIP1 rs552752779 (MAF: 75% vs. 6.25%, OR 45.00, 95% CI 9.43-243.32), ERBB2 rs527779103 (MAF: 62.5% vs. 7.29%, OR 21.19, 95% CI 5.11-94.32), ERCC2 rs121913016 (MAF: 56.25% vs. 7.29%, OR 16.34, 95% CI 4.02-70.41), MSH6 rs2020912 (MAF: 56.25% vs. 1.04%, OR 122.13, 95% CI 12.29-2985.48) as risk factors for triple negative breast cancer.
|
30136158 |
2018 |
|
rs552752779
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Whole exome sequencing in triple negative breast cancer cases (n = 8) and targeted sequencing in healthy controls (n = 48) revealed BRIP1 rs552752779 (MAF: 75% vs. 6.25%, OR 45.00, 95% CI 9.43-243.32), ERBB2 rs527779103 (MAF: 62.5% vs. 7.29%, OR 21.19, 95% CI 5.11-94.32), ERCC2 rs121913016 (MAF: 56.25% vs. 7.29%, OR 16.34, 95% CI 4.02-70.41), MSH6 rs2020912 (MAF: 56.25% vs. 1.04%, OR 122.13, 95% CI 12.29-2985.48) as risk factors for triple negative breast cancer.
|
30136158 |
2018 |
|
rs635538
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The interactions among exm408776, exm1278309, rs316389, rs1651654, rs635538, exm1292477 SNPs inflate the risk for TNBC further.
|
28918577 |
2018 |
|
rs72631823
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our case-control study suggests that pre-miR34a rs72631823 A allele is associated with increased triple negative breast cancer risk.
|
30651924 |
2018 |
|
rs769483475
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Collectively, these findings provide the first functional evidence for the M276I mutation in promoting TNBC progression.
|
30093560 |
2018 |
|
rs780439043
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Transcriptome profiling identified ADORA2B as up-regulated in basal-like TNBC cell lines with R248Q-mutated TP53, with shRNA-screening suggesting the potential for a synthetic-lethal interaction between these genes.
|
30349649 |
2018 |
|
rs9485372
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After grouping breast cancer subtypes, significantly reduced survival was associated with the variant alleles of rs9485372 for luminal A and rs4415084 for triple negative breast cancer.
|
30285756 |
2018 |
|
rs1436904
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our findings demonstrate that the GWAS-identified 18q11.2 CHST9 rs1436904 polymorphism significantly contributes to prognosis of early-stage TNBC, suggesting its clinical potential in the screening of high-risk TNBC patients for recurrence and the possibility of patient-tailored therapeutic decisions.
|
28924212 |
2017 |
|
rs144567652
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The frequency of the FANCM c.5791C>T mutation was higher among breast cancer cases than in controls (OR 1.94, 95% CI 0.87-4.32, P = 0.11), with a statistically significant association with triple-negative breast cancer (OR 5.14, 95% CI 1.65-16.0, P = 0.005).
|
28702895 |
2017 |
|
rs1485579458
|
|
|
0.010 |
GeneticVariation |
BEFREE |
GLCE rs3865014 (Val597Ile) polymorphism is associated with breast cancer susceptibility and triple-negative breast cancer in Siberian population.
|
28734894 |
2017 |
|
rs3865014
|
|
|
0.010 |
GeneticVariation |
BEFREE |
GLCE rs3865014 (Val597Ile) polymorphism is associated with breast cancer susceptibility and triple-negative breast cancer in Siberian population.
|
28734894 |
2017 |
|
rs527616
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our study is aimed to evaluate the prognostic value of the genome wide association study (GWAS)-identified CHST9 rs1436904 and AQP4 rs527616 genetic variants in our established early-stage TNBC sample database.
|
28924212 |
2017 |
|
rs564064363
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Three PDXs were selected for their lack of PTEN expression by immunohistochemistry: a triple-negative breast cancer (TNBC), a <i>KRAS</i> G12R low-grade serous ovarian cancer (LGSOC), and <i>KRAS</i> G12C and <i>TP53</i> R181P lung adenocarcinoma (LADC).
|
29156674 |
2017 |